AMSTERDAM, the Netherlands, Feb. 28 2007 - Amsterdam Molecular Therapeutics BV (AMT), a leader in the field of human gene therapy, announces that it has obtained exclusive worldwide rights to develop and commercialise AMT-020 as a therapeutic product from UTE CIMA, Proyecto de Biomedicina CIMA, S.L. and Digna Biotech (all parties part of the University of Navarra, Pamplona, Spain).
